Sutro Biopharma (STRO) Other financing activities (2017 - 2025)

Sutro Biopharma has reported Other financing activities for 9 years, with the latest figure at -$1000.0 in Q4 2025.

• Quarterly Other financing activities rose 100.0% year-over-year to -$1000.0 in Q4 2025, while the trailing twelve-month figure through Sep 2025 was -$71.3 million (down 10.7% YoY) and the FY2024 annual result came in at $271000.0, down 13.69% from the prior year.
• Other financing activities rose to -$1000.0 in Q4 2025 per STRO's latest filing, from -$245000.0 in the prior quarter.
• Over five years, Other financing activities peaked at $135.9 million in Q3 2023 and troughed at -$135.9 million in Q4 2023.
• A 5-year average of $196352.9 and a median of $246000.0 in 2025 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2022 and 2024: Other financing activities sank 5746.81% in 2022, then surged 9220.05% in 2024.
• Over 5 years, Other financing activities stood at $720000.0 in 2021, then tumbled by 5746.81% to -$40.7 million in 2022, then sank by 234.25% to -$135.9 million in 2023, then soared by 47.57% to -$71.3 million in 2024, then soared by 100.0% to -$1000.0 in 2025.
• According to Business Quant data, Other financing activities over the past three periods registered -$1000.0, -$245000.0, and $246000.0 for Q4 2025, Q3 2025, and Q1 2025 respectively.